Jianping Weng

A lifespan-scale single-cell atlas defines an early-childhood immunometabolic transition linked to age-referenced immune states

The paper constructs a lifespan single-cell atlas of immune cells, identifies an early-childhood immunometabolic transition around age 6, and develops an age-referenced framework for immune-state analysis.

Tirzepatide attenuates atherosclerosis through weight loss-independent anti-inflammatory mechanisms

This paper shows tirzepatide reduces atherosclerosis independently of weight loss by directly targeting vascular inflammation through the cAMP/PKA/eNOS pathway.

Desert hedgehog enhances endothelial resilience and prevents atherosclerosis by mitigating PAI-1 signaling

This study identifies desert hedgehog (DHH) as a resilience factor that prevents atherosclerosis by inhibiting PAI-1 signaling and endothelial mesenchymal transition.

Neratinib, a clinical drug against breast cancer, protects against atherosclerosis via ASK1 inhibition

Neratinib reduces atherosclerosis by inhibiting ASK1-mediated endothelial inflammation, showing potential as a repurposed drug for vascular disease.

Re-evaluating the Impact of Biological Sex on Atherosclerosis in Apoe-/- and Ldlr-/- mice

This study evaluates the impact of biological sex on atherosclerosis in Apoe-/- and Ldlr-/- mice, finding sex-dependent differences in plaque burden and metabolic parameters.

Colchicine Inhibits Smooth Muscle Cell Phenotypic Switch and Aortic Dissection in Mice

This study shows colchicine prevents aortic dissection in mice by inhibiting vascular inflammation and smooth muscle cell phenotypic transformation.

Endothelial MICU1 protects against vascular inflammation and atherosclerosis by inhibiting mitochondrial calcium uptake

This study shows that endothelial MICU1 prevents vascular inflammation and atherosclerosis by maintaining mitochondrial calcium homeostasis and reducing mitochondrial reactive oxygen species.

Single-cell analysis of severe COVID-19 patients reveals a monocyte-driven inflammatory storm attenuated by Tocilizumab

The paper uses single-cell analysis to show that Tocilizumab reduces monocyte-driven inflammation in severe COVID-19 but does not fully suppress immune responses.